Biotech

Adaptimmune Therapeutics (NASDAQ:ADAP) has announced that the US Food and Drug Administration (FDA) has granted it orphan drug designation for its SPEAR T-cells targeting MAGE-A4 to treat soft tissue sarcomas. As quoted in the press release:  Orphan Designation by FDA was created to encourage the development of drugs for rare diseases, such as sarcomas. “We …

Adaptimmune Therapeutics (NASDAQ:ADAP) has announced that the US Food and Drug Administration (FDA) has granted it orphan drug designation for its SPEAR T-cells targeting MAGE-A4 to treat soft tissue sarcomas.

As quoted in the press release:

Orphan Designation by FDA was created to encourage the development of drugs for rare diseases, such as sarcomas.

“We recently started SPEARHEAD-1 treating patients with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS), with the aim to launch ADP-A2M4 in 2022,” said Elliot Norry, Adaptimmune’s interim Chief Medical Officer. “This orphan drug status is another key milestone in achieving our goal of providing this much-needed therapy to people living with these rare and deadly cancers, for which there are few other treatment options.”

Click here to read the full press release.

MARKETS

Markets
TSX18762.68-315.96
TSXV613.58-12.76
DOW30681.12-348.19
S&P 5003776.25-42.58
NASD11012.41-165.48
ASX6700.20-63.40

COMMODITIES

Commodities
Gold1808.94-9.88
Silver20.37-0.37
Copper3.71-0.07
Palladium1893.00-69.00
Platinum905.00-14.00
Oil106.63-3.15
Heating Oil3.79-0.16
Natural Gas5.90-0.59

DOWNLOAD FREE REPORTS

×